van Es, S. C., Velleman, T., Elias, S. G., Bensch, F., Brouwers, A. H., Glaudemans, A. W. J. M., Kwee, T. C., Woltman-van Iersel, M., Maduro, J. H., Oosting, S. F., de Vries, E. G. E., & Schröder, C. P. (2021). Assessment of Bone Lesions with 18F-FDG-PET Compared to 99mTechnetium Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management. Journal of Nuclear Medicine, 62(1). https://doi.org/10.2967/jnumed.120.244640

van Es, S. C., van der Vegt, B., Bensch, F., Gerritse, S., van Helden, E. J., Boon, E., Angus, L., Overbosch, J., Menke-van der Houven van Oordt, C. W., Verheul, H. M., van Herpen, C. M. L., Jager, A., Oosting, S. F., de Vries, E. G. E., & Schröder, C. P. (2019). Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results. American Journal of Surgical Pathology, 43(10), 1355-1360. https://doi.org/10.1097/PAS.0000000000001321

Jauw, Y. W. S., Bensch, F., Brouwers, A. H., Hoekstra, O. S., Zijlstra, J. M., Pieplenbosch, S., Schröder, C. P., Zweegman, S., van Dongen, G. A. M. S., van Oordt, C. W. M. D. H., de Vries, E. G. E., de Vet, H. C. W., Boellaard, R., & Huisman, M. C. (2019). Interobserver reproducibility of tumor uptake quantification with Zr-89-immuno-PET: a multicenter analysis. European Journal of Nuclear Medicine and Molecular Imaging, 46(9), 1840-1849. https://doi.org/10.1007/s00259-019-04377-6

Bensch, F., van der Veen, E. L., Lub-de Hooge, M. N., Jorritsma-Smit, A., Boellaard, R., Kok, I. C., Oosting, S. F., Schröder, C. P., Hiltermann, T. J. N., van der Wekken, A. J., Groen, H. J. M., Kwee, T. C., Elias, S. G., Gietema, J. A., Bohorquez, S. S., de Crespigny, A., Williams, S-P., Mancao, C., Brouwers, A. H., ... de Vries, E. G. E. (2018). Zr-89-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nature Medicine, 24(12), 1852-1858. https://doi.org/10.1038/s41591-018-0255-8

Bensch, F., Brouwers, A. H., Lub-de Hooge, M. N., de Jong, J. R., van der Vegt, B., Sleijfer, S., de Vries, E. G. E., & Schröder, C. P. (2018). 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. European Journal of Nuclear Medicine and Molecular Imaging, 45(13), 2300-2306. https://doi.org/10.1007/s00259-018-4099-8

van der Veen, E. L., Bensch, F., Glaudemans, A. W. J. M., Lub-de Hooge, M. N., & de Vries, E. G. E. (2018). Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. CANCER TREATMENT REVIEWS, 70, 232-244. https://doi.org/10.1016/j.ctrv.2018.09.007

Bensch, F., Smeenk, M. M., van Es, S. C., de Jong, J. R., Schröder, C. P., Oosting, S. F., Lub-de Hooge, M. N., Menke-van der Houven van Oordt, C. W., Brouwers, A. H., Boellaard, R., & de Vries, E. G. E. (2018). Comparative biodistribution analysis across four different Zr-monoclonal antibody tracers-The first step towards an imaging warehouse. Theranostics, 8(16), 4295-4304. https://doi.org/10.7150/thno.26370

Bensch, F., Lamberts, L. E., Smeenk, M. M., Jorritsma-Smit, A., Lub-de Hooge, M. N., Terwisscha van Scheltinga, A. G. T., de Jong, J. R., Gietema, J. A., Schröder, C. P., Thomas, M., Jacob, W., Abiraj, K., Adessi, C., Meneses-Lorente, G., James, I., Weisser, M., Brouwers, A. H., & de Vries, E. G. (2017). Zr-89-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors. Clinical Cancer Research, 23(20), 6128-6137. https://doi.org/10.1158/1078-0432.CCR-17-0311

Bensch, F., van der Veen, E., Jorritsma, A., Lub-de Hooge, M., Boellaard, R., Oosting, S., Schröder, C., Hiltermann, J., van der Wekken, A., Groen, H., Fine, B., McKnight, N., Bohorquez, S. S., Williams, S., Veronese, L., Mancao, C., Brouwers, A. H., & de Vries, E. (2017). First-in-human PET imaging with the PD-L1 antibody Zr-89-atezolizumab. Cancer Research, 77. https://doi.org/10.1158/1538-7445.AM2017-CT017

Schröder, C. P., Bensch, F., Brouwers, A. H., Lub-de Hooge, M. N., de Jong, J. R., van der Vegt, B., Sleijfer, S., & de Vries, E. G. (2017). Clinical value of Zr-89-trastuzumab PET in HER2-positive breast cancer patients with a clinical dilemma. Cancer Research, 77(4). https://doi.org/10.1158/1538-7445.SABCS16-P5-03-06

Lamberts, T. E., Menke-van der Houven van Oordt, C. W., Ter Weele, E. J., Bensch, F., Smeenk, M. M., Voortman, J., Hoekstra, O. S., Williams, S. P., Fine, B. M., Maslyar, D., de Jong, J. R., Gietema, J. A., Schröder, C. P., Bongaerts, A. H. H., Lub-de Hooge, M. N., Verheul, H. M. W., Sanabria Bohorquez, S., Glaudemans, A. W. J. M., & de Vries, E. G. (2015). ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment. Clinical Cancer Research, 22(7), 1642-1652. https://doi.org/10.1158/1078-0432.CCR-15-1272

den Hollander, M. W., Bensch, F., Glaudemans, A. W. J. M., Oude Munnink, T. H., Enting, R. H., den Dunnen, W. F. A., Heesters, M. A. A. M., Kruyt, F. A. E., Lub-de Hooge, M. N., de Groot, J. C., Pearlberg, J., Gietema, J. A., de Vries, E. G. E., & Walenkamp, A. M. E. (2015). TGF-beta Antibody Uptake in Recurrent High-Grade Glioma Imaged with Zr-89-Fresolimumab PET. Journal of Nuclear Medicine, 56(9), 1310-1314. https://doi.org/10.2967/jnumed.115.154401

van Helden, E. J., van Es, S., Bensch, F., Boon, E., Menke-van der Houven van Oordt, C. W., Schröder, C., van Herpen, C. M. L., Brouwers, A., Glaudemans, A. W. J. M., Hoekstra, O. S., Oyen, W. J. G., van der Graaf, W. T. A., Verheul, H. M. V., & de Vries, E. G. E. (2015). IMPACT: op weg naar een gepersonaliseerde antikankerbehandeling met behulp van moleculaire beeldvorming. Drie lopende studies voor mamma-, colorectaal en niercelcarcinoom. Nederlands Tijdschrift voor Oncologie, 12(3), 114-120.

Bensch, F., van Rooijen, J. M., Schröder, C. P., & Reyners, A. K. L. (2015). A 21-Year-Old Patient With a HER2-Positive Colorectal Cancer. Gastroenterology, 148(1), 20-21. https://doi.org/10.1053/j.gastro.2014.09.046

Lamberts, L. E., Menke-van der Houven van Oordt, C. W., Bensch, F., Voortman, J., Hoekstra, O. S., Maslyar, D., Williams, S. P., Fine, B. M., Bongaerts, A. H., Gietema, J. A., Schroder, C. P., Weele, E. J. T., Hooge, M. N. L-D., Verheul, H. M., Sanabria, S., Glaudemans, A. W. J. M., & Vries, de, E. G. E. (2014). 1627PPET-IMAGING WITH 89ZR-LABELED ANTI-MESOTHELIN (MSLN) ANTIBODY IN PATIENTS WITH PANCREATIC CANCER (PC) OR OVARIAN CANCER (OC). Annals of Oncology, 25(Supplement 4), iv562. https://doi.org/10.1093/annonc/mdu358.58

Kol, A., Terwisscha Van Scheltinga, A., Timmer-Bosscha, H., Lamberts, L. E., Bensch, F., de Vries, E., & Schroder, C. P. (2014). HER3, serious partner in crime Therapeutic approaches and potential biomarkers for effect of HER3-targeting. Pharmacology & Therapeutics, 143(1), 1-11. https://doi.org/10.1016/j.pharmthera.2014.01.005

de Vries, L., van Kruchten, M., Lamberts, L., Bensch, F., Brouwers, A., Lub-de-Hooge, M., van Dam, G., Schroder, C., & Hospers, G. (2014). Selection to targeted treatment in advanced disease. European Journal of Cancer, 50, S42.

Bensch, F., van Kruchten, M., Lamberts, L., Schroder, C. P., Hospers, G. A. P., Brouwers, A. H., van Vugt, M. A. T. M., & de Vries, E. G. E. (2013). Molecular imaging for monitoring treatment response in breast cancer patients. European Journal of Pharmacology, 717(1-3), 2-11. https://doi.org/10.1016/j.ejphar.2013.01.079

den Hollander, M. W., Bensch, F., Glaudemans, A. W. J. M., Enting, R. H., Bunskoek, S., Munnink, T. H. O., Lub-de Hooge, M. N., Pearlberg, J., Gietema, J. A., de Vries, L., & Walenkamp, A. M. E. (2013). (89)zr-GC1008 PET imaging and GC1008 treatment of recurrent glioma patients. Journal of Clinical Oncology, 31(15). http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=27&SID=Q2OcaLCYHfq4ryZlDpd&page=1&doc=1